Charles Schwab
VYNE icon

Charles Schwab’s VYNE Therapeutics VYNE Stock Holding History

Charles Schwab’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,120
Closed -$71K – 3546
2021
Q2 		$71K Sell
1,120
-4,380
-80% -$347K ﹤0.01% 3326
2021
Q1 		$678K Buy
5,500
+534
+11% +$77.4K ﹤0.01% 2978
2020
Q4 		$565K Hold
4,966
– – ﹤0.01% 2945
2020
Q3 		$594K Buy
4,966
+997
+25% +$116K ﹤0.01% 2830
2020
Q2 		$495K Buy
3,969
+2,611
+192% +$354K ﹤0.01% 2832
2020
Q1 		$262K Buy
1,358
+911
+204% +$286K ﹤0.01% 2930
2019
Q4 		$150K Hold
447
– – ﹤0.01% 3071
2019
Q3 		$145K Sell
447
-295
-40% -$95.2K ﹤0.01% 3076
2019
Q2 		$321K Buy
742
+174
+31% +$86.1K ﹤0.01% 2987
2019
Q1 		$322K Buy
568
+35
+7% +$16.8K ﹤0.01% 2924
2018
Q4 		$158K Sell
533
-9
-2% -$4.03K ﹤0.01% 3045
2018
Q3 		$385K Buy
542
+197
+57% +$122K ﹤0.01% 2922
2018
Q2 		$202K Sell
345
-56
-14% -$43.5K ﹤0.01% 3060
2018
Q1 		$1.08M Buy
+401
New +$975K ﹤0.01% 2491

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab's VYNE Position: Q3 2021 in Review

Charles Schwab sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 1,120 shares — an estimated $71K sold.

Charles Schwab first reported a position in VYNE in Q1 2018 and held it in 14 quarters. The position peaked at $1.08M in Q1 2018. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • Charles Schwab reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 1,120 VYNE Therapeutics shares in Q3 2021, an estimated $71K.
  • Charles Schwab first reported a position in VYNE Therapeutics in Q1 2018 and held it in 14 quarters.
  • Charles Schwab's VYNE Therapeutics position peaked at $1.08M in Q1 2018.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.